Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Developing predictive assays: the phenotypic screening "rule of 3".

Science translational medicine - 24 Jun 2015

Vincent Fabien, Loria Paula, Pregel Marko, Stanton Robert, Kitching Linda, Nocka Karl, Doyonnas Regis, Steppan Claire, Gilbert Adam, Schroeter Thomas, Peakman Marie-Claire

Abstract excerpt

Phenotypic drug discovery approaches can positively affect the translation of preclinical findings to patients. However, not all phenotypic assays are created equal. A critical question then follows: What are the characteristics of the optimal assays? We analyze this question and propose three sp...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biological Assay
Share to Drug Evaluation, Preclinical
Share to Endpoint Determination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenotype

Source

Identifiers

PMID: 26109101
DOI: 10.1126/scitranslmed.aab1201

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-26109101-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Developing predictive assays: the phenotypic screening "rule of 3".PMID 26109101Read ↗

The Power of Sophisticated Phenotypic Screening and Modern Mechanism-of-Action Methods.Semantic proximity Read ↗

Perspectives on phenotypic screening-Screen Design and Assay Technology Special Interest Group.Semantic proximity Read ↗

The future of phenotypic drug discovery.Semantic proximity Read ↗

How Phenotypic Screening Influenced Drug Discovery: Lessons from Five Years of Practice.Semantic proximity Read ↗

Bridging the gap between target-based and phenotypic-based drug discovery.Semantic proximity Read ↗

The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Phenotypic Drug Discovery.Semantic proximity Read ↗

Neoclassic drug discovery: the case for lead generation using phenotypic and functional approaches.Semantic proximity Read ↗

Innovating cancer drug discovery with refined phenotypic screens.Semantic proximity Read ↗

Hit Triage and Validation in Phenotypic Screening: Considerations and Strategies.Semantic proximity Read ↗

Next-generation phenotypic screening.Semantic proximity Read ↗

Phenotypic approach to drug discovery.Semantic proximity Read ↗

Open innovation for phenotypic drug discovery: The PD2 assay panel.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.